Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Universidad del Valle
2007
|
| Sujets: | |
| Accès en ligne: | https://www.redalyc.org/articulo.oa?id=28338112 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Table des matières:
- Glucose-6-phosphate dehydrogenase (G6PD). Response of the human erythrocyte and another cells to the decrease in their activity Javier Fernando Bonilla Magda Carolina Sánchez Lilian Chuaire Medicina Glucose Genetics Physiology Erythrocyte Epidemiology Glucose-6-phosphate dehydrogenase is the first enzyme in the pentose phosphate pathway and the main intracellular sourceof reduced nicotidamineadenine nucleotidephosphate (NADPH), involved in diverse physiological processes such as antioxidantdefense, (for instance in the erythrocyte) endothelial growth modulation, erithropoyesis, vascularization and phagocitosis. G6PDHdeficiency is the most common X-chromosome-linked enzymopathy in human beings. Although it is present in any type cell, itsabsolute deficiency is incompatible with life. According to WHO, 400 million people are affected by G6PD deficiency in the worldbut in Colombia, the severe form prevalence is about 3% to 7%. There are no data related to slight and moderate alterations, thatalso have clinical effects. This paper reviews some G6PD biomolecular aspects, its classification according to activity andelectrophoretic mobility, as well as some main clinical aspects related to its activity alteration 2007 artículo científico 0120-8322 https://www.redalyc.org/articulo.oa?id=28338112 en http://www.redalyc.org/revista.oa?id=283 Colombia Médica application/pdf Universidad del Valle Colombia Médica (Colombia) Num.1 Vol.38